The p53 pathway as a target in cancer therapeutics: obstacles and promise
about
Oncogenic Intra-p53 Family Member Interactions in Human CancersResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53Synthetic lethality in lung cancer and translation to clinical therapiesStructure and activity analysis of Inauhzin analogs as novel antitumor compounds that induce p53 and inhibit cell growthp53-mediated heterochromatin reorganization regulates its cell fate decisions.p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes.High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activityMouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomesp53 Family and Cellular Stress Responses in Cancer.p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters.Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interactionSmall-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory AxisRY10-4 Inhibits the Proliferation of Human Hepatocellular Cancer HepG2 Cells by Inducing Apoptosis In Vitro and In VivoWip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xL ratioGenetic changes in squamous cell lung cancer: a reviewGallium-containing anticancer compounds.Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.Therapeutic targeting of the p53 pathway in cancer stem cells.Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation.Pharmacological activation of p53 in cancer cellsA fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradationMathematical modeling for novel cancer drug discovery and development.Wip1 contributes to cell homeostasis maintained by the steady-state level of Wtp53.Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 ComplexATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.Molecularly targeted therapies for p53-mutant cancers.DNA-damaging drug-induced apoptosis sensitized by N-myc in neuroblastoma cells.Stochastic and Deterministic Models of Cellular p53 Regulation.Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling.Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.The genomics of lung adenocarcinoma: opportunities for targeted therapies.RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
P2860
Q26749382-21DB4DC3-E1F2-4CA4-B44A-C5442254732DQ27006998-722044C3-D417-4665-8E6B-CC3CA28AA61EQ28072904-1C0EA169-06F3-41BF-8A9A-08BD042685ABQ28484540-37EA1E2A-F593-4C16-B063-6FB7BA8592E7Q33565827-8D74C8A6-B647-4D88-A1C4-0CBEE694BA8BQ33794127-B6DDC719-001C-49FB-81B0-9A97E6522FD6Q34274477-FBCC789E-B66D-4937-B870-2BB787BFAF4EQ34374191-E7ADBDA2-89C8-441A-84F2-008DF4B584ECQ34377287-74DF4C97-5C55-4FC9-B66E-F8C81D673F37Q34801565-BE50B652-6EE6-43C3-8ECC-E868403359CEQ34964647-0EA7A6B3-6985-4C0D-B5B6-017E6E8C5678Q35492010-4158D14B-B696-4943-8B84-F5D518F65482Q35643329-95E67B37-9B2F-4A7B-AB01-763E3B6CC811Q35759870-7910BB4D-1A97-4917-8D23-CEA238622F3FQ35956464-56FF17B1-4B1C-4926-B3CC-611626813EBBQ35984061-B9C0CAF8-416A-4E36-884B-FAA7E7806FA0Q36115735-213A597B-F6CC-46AA-90D4-08FC1394FE41Q36616612-1A562E6D-3562-45B9-B0C4-1C79232E8686Q36782143-DA835752-2240-48DD-8A8A-72D5FF323CB9Q36833275-B11248DC-D3AA-4E17-B5DA-CD2AC571CF26Q36917788-93E78311-CF89-4E59-ADA8-76C4DDD13782Q36944526-1CF9B355-372B-4394-B710-6BF67F11D412Q37191174-648D654E-7D52-46FD-8195-9E4A7788A4D8Q37364980-0D3B5BCA-6920-46C0-84BC-FDA8A54A08D9Q37518896-627077A4-621D-4433-8001-9C02168CC05DQ37577477-C4BF89A3-97D2-45F8-8982-53F459DC033EQ37689443-61E62CAC-1661-46E8-9FB8-64C22422C2A2Q38233988-F8A0E860-D42E-4085-B1F1-3AFC02FB0982Q38562746-ABA4D59B-D440-4302-90F6-DC836E8E785AQ38709284-9DE4DF28-0218-42EE-8C77-60D24E0855C3Q38966129-EB63F9A9-622C-45CA-81EA-7931A1AA14D8Q39029101-1267995E-F3F4-4831-B62C-986D291AE21DQ39337933-D63EC989-66CB-4123-97C5-AA5E6311B5DCQ39393193-7B097070-0BE4-4765-A6EE-23E9526EA853Q39471884-372648E4-295E-4783-909D-5B4397DDD8DCQ39492626-5E70DA7E-A779-40DB-BD85-CFDB41C425B8Q40311218-9DB4D5CF-AC93-464E-B334-4262E3E2DC1FQ41459790-4D585322-D6CB-4A53-94DC-7FE1520DDCE8Q41891513-ACB0A2D1-CFFE-4C1D-B4C3-DE88564BD2DBQ46356056-7358C5EE-DED5-4E88-AA1D-72933EF2570D
P2860
The p53 pathway as a target in cancer therapeutics: obstacles and promise
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The p53 pathway as a target in cancer therapeutics: obstacles and promise
@ast
The p53 pathway as a target in cancer therapeutics: obstacles and promise
@en
The p53 pathway as a target in cancer therapeutics: obstacles and promise.
@nl
type
label
The p53 pathway as a target in cancer therapeutics: obstacles and promise
@ast
The p53 pathway as a target in cancer therapeutics: obstacles and promise
@en
The p53 pathway as a target in cancer therapeutics: obstacles and promise.
@nl
prefLabel
The p53 pathway as a target in cancer therapeutics: obstacles and promise
@ast
The p53 pathway as a target in cancer therapeutics: obstacles and promise
@en
The p53 pathway as a target in cancer therapeutics: obstacles and promise.
@nl
P2860
P3181
P1476
The p53 pathway as a target in cancer therapeutics: obstacles and promise
@en
P2093
P2860
P3181
P356
10.1126/SCITRANSLMED.3001366
P407
P577
2011-01-05T00:00:00Z